JNJ

Hailshadow Johnson & Johnson (NYSE:JNJ) announced Tuesday that its FDA-approved multiple myeloma therapy Darzalex Faspro in a combination regimen cut the risk of disease progression or death by 58% compared to standard of care in a…

The pharmaceutical sector recorded the highest sales of about $13.71 billion, followed by MedTech with total sales of about $7.78 billion, and the rest is due from the consumer health sector. Johnson & Johnson (NYSE:JNJ), one of…